|
1
|
Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer.
|
N Engl J Med
|
2011
|
12.45
|
|
2
|
Novel anticancer targets: revisiting ERBB2 and discovering ERBB3.
|
Nat Rev Cancer
|
2009
|
6.28
|
|
3
|
Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer.
|
N Engl J Med
|
2015
|
4.97
|
|
4
|
Treatment of HER2-positive breast cancer: current status and future perspectives.
|
Nat Rev Clin Oncol
|
2011
|
4.12
|
|
5
|
Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study.
|
Lancet Oncol
|
2013
|
3.87
|
|
6
|
Combinatorial drug therapy for cancer in the post-genomic era.
|
Nat Biotechnol
|
2012
|
3.10
|
|
7
|
Biomarker analyses in CLEOPATRA: a phase III, placebo-controlled study of pertuzumab in human epidermal growth factor receptor 2-positive, first-line metastatic breast cancer.
|
J Clin Oncol
|
2014
|
2.72
|
|
8
|
Antibody-based therapeutics to watch in 2011.
|
MAbs
|
2011
|
2.00
|
|
9
|
Intrinsic subtypes, PIK3CA mutation, and the degree of benefit from adjuvant trastuzumab in the NSABP B-31 trial.
|
J Clin Oncol
|
2015
|
1.99
|
|
10
|
Antibodies to watch in 2010.
|
MAbs
|
2010
|
1.90
|
|
11
|
Targeting the ERBB family in cancer: couples therapy.
|
Nat Rev Cancer
|
2013
|
1.72
|
|
12
|
Cardiac tolerability of pertuzumab plus trastuzumab plus docetaxel in patients with HER2-positive metastatic breast cancer in CLEOPATRA: a randomized, double-blind, placebo-controlled phase III study.
|
Oncologist
|
2013
|
1.35
|
|
13
|
Current approaches and future directions in the treatment of HER2-positive breast cancer.
|
Cancer Treat Rev
|
2012
|
1.23
|
|
14
|
Incidence of central nervous system metastases in patients with HER2-positive metastatic breast cancer treated with pertuzumab, trastuzumab, and docetaxel: results from the randomized phase III study CLEOPATRA.
|
Ann Oncol
|
2014
|
1.19
|
|
15
|
Targeted therapy for HER2 positive breast cancer.
|
J Hematol Oncol
|
2013
|
1.19
|
|
16
|
Beyond trastuzumab: novel therapeutic strategies in HER2-positive metastatic breast cancer.
|
Br J Cancer
|
2012
|
1.12
|
|
17
|
Challenges in the Treatment of Triple Negative and HER2-Overexpressing Breast Cancer.
|
J Surg Sci
|
2013
|
1.10
|
|
18
|
Health-related quality-of-life assessment in CLEOPATRA, a phase III study combining pertuzumab with trastuzumab and docetaxel in metastatic breast cancer.
|
Ann Oncol
|
2013
|
1.08
|
|
19
|
CLEOPATRA: a phase III evaluation of pertuzumab and trastuzumab for HER2-positive metastatic breast cancer.
|
Clin Breast Cancer
|
2010
|
1.08
|
|
20
|
Pooled analysis of cardiac safety in patients with cancer treated with pertuzumab.
|
Ann Oncol
|
2011
|
1.00
|
|
21
|
PI3K inhibitors as new cancer therapeutics: implications for clinical trial design.
|
Onco Targets Ther
|
2016
|
0.96
|
|
22
|
Strategies to overcome trastuzumab resistance in HER2-overexpressing breast cancers: focus on new data from clinical trials.
|
BMC Med
|
2014
|
0.96
|
|
23
|
Personalized drug combinations to overcome trastuzumab resistance in HER2-positive breast cancer.
|
Biochim Biophys Acta
|
2014
|
0.96
|
|
24
|
A growing family: adding mutated Erbb4 as a novel cancer target.
|
Cell Cycle
|
2010
|
0.95
|
|
25
|
Safety profile of Pertuzumab with Trastuzumab and Docetaxel in patients from Asia with human epidermal growth factor receptor 2-positive metastatic breast cancer: results from the phase III trial CLEOPATRA.
|
Oncologist
|
2014
|
0.95
|
|
26
|
Mechanisms of Resistance to Trastuzumab and Novel Therapeutic Strategies in HER2-Positive Breast Cancer.
|
Int J Breast Cancer
|
2012
|
0.92
|
|
27
|
Peptide vaccines and targeting HER and VEGF proteins may offer a potentially new paradigm in cancer immunotherapy.
|
Future Oncol
|
2012
|
0.88
|
|
28
|
Back to the future: recombinant polyclonal antibody therapeutics.
|
Curr Opin Chem Eng
|
2013
|
0.86
|
|
29
|
Treatment of older patients with HER2-positive metastatic breast cancer with pertuzumab, trastuzumab, and docetaxel: subgroup analyses from a randomized, double-blind, placebo-controlled phase III trial (CLEOPATRA).
|
Breast Cancer Res Treat
|
2013
|
0.81
|
|
30
|
Tumour-infiltrating lymphocytes in advanced HER2-positive breast cancer treated with pertuzumab or placebo in addition to trastuzumab and docetaxel: a retrospective analysis of the CLEOPATRA study.
|
Lancet Oncol
|
2016
|
0.79
|
|
31
|
Ligand-based receptor tyrosine kinase partial agonists: New paradigm for cancer drug discovery?
|
Expert Opin Drug Discov
|
2011
|
0.79
|
|
32
|
Targeted Therapies in HER2-Positive Breast Cancer - a Systematic Review.
|
Breast Care (Basel)
|
2015
|
0.77
|
|
33
|
New clinical advances in immunotherapy for the treatment of solid tumours.
|
Immunology
|
2015
|
0.76
|
|
34
|
Monoclonal antibodies and Fc fragments for treating solid tumors.
|
Biologics
|
2012
|
0.75
|
|
35
|
Resistance to therapy in estrogen receptor positive and human epidermal growth factor 2 positive breast cancers: progress with latest therapeutic strategies.
|
Ther Adv Med Oncol
|
2016
|
0.75
|
|
36
|
Novel combinations for the treatment of metastatic breast cancer.
|
Cancers (Basel)
|
2010
|
0.75
|
|
37
|
Optimal management of breast cancer in the elderly patient: current perspectives.
|
Clin Interv Aging
|
2015
|
0.75
|
|
38
|
Trastuzumab emtansine in the treatment of HER2-positive metastatic breast cancer in Japanese patients.
|
Breast Cancer (Dove Med Press)
|
2014
|
0.75
|